MERCK KGAA O.N. news, videos and press releases
For more news please use our advanced search feature.
MERCK KGAA O.N. - More news...
MERCK KGAA O.N. - More news...
- EQS-Adhoc: Merck KGaA: Strong 2nd Quarter, Guidance raised
- EQS-Adhoc: Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
- EQS-Adhoc: Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide
- EMD Electronics Celebrates Opening of New Arizona Factory, Contributing to the State's Growing Semiconductor Industry
- Merck KGaA, Darmstadt, Germany's New Barrier Materials Offer Superior Flexibility, Reliability, and Longer Lifetime in OLED Devices
- EMD Electronics Expands Renewable Energy Through Virtual Power Purchase Agreement With Recurrent Energy
- EMD Electronics Expands Semiconductor Manufacturing Capacities for the World's Largest Integrated Specialty Gases Facility in Hometown, Pennsylvania
- DGAP-Adhoc: Merck KGaA raises forecast for full year 2021
- Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity
- DGAP-Adhoc: Merck KGaA raises forecast for full year 2021
- Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
- DGAP-Adhoc: Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)
- DGAP-Adhoc: Merck KGaA: Merck KGaA reverses provision for lawsuit in the amount of EUR 365 million
- /C O R R E C T I O N -- EMD Serono/
- Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020
- Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
- New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care
- Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
- Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
- DGAP-Adhoc: Merck KGaA: Merck Proposes to Acquire Versum for USD 48 per Share and to Create a Leading Electronic Materials Player
- DGAP-Adhoc: Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology
- Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
- Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
- Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
- Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
- Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
- Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
- Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets
- Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma
- Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018
